Groundbreaking Trial Tests Time-Restricted Eating in Huntington’s Disease

Researchers are launching a pioneering 12-week clinical trial to evaluate time-restricted eating (TRE) in early-stage Huntington’s disease (HD) patients. The study, funded by the National Institutes of Health (NIH), builds on compelling animal data showing TRE improved motor function in HD mice by 15% in a 2023 pilot study.

The Science Behind TRE and Neurodegeneration

Recent findings published in The Lancet (June 2024) revealed TRE reduced inflammation markers by 30% in neurodegenerative patients. This metabolic intervention may create a protective environment for neurons by enhancing autophagy and reducing oxidative stress, explained Dr. Sarah Matthews, lead author of the Lancet study.

The trial will track key biomarkers including:

• Brain-derived neurotrophic factor (BDNF) levels
• Glutathione concentrations
• Mitochondrial function markers

Synergy With Emerging HD Therapies

Notably, the FDA fast-tracked a TRE-based HD therapy in May 2024 after animal studies demonstrated reduced mutant huntingtin aggregation. When combined with RNA-targeting drugs, TRE might enhance huntingtin clearance through metabolic synchronization, noted Dr. Raymond Chang in a JAMA Neurology editorial.

Practical Implementation for HD Patients

The trial protocol recommends:

• 8-hour eating windows tailored to individual energy needs
• Gradual adaptation over 2-3 weeks
• Use of wearable tech (like Levels) to monitor metabolic responses

Parallel research in Parkinson’s disease (published in Nature, June 2024) suggests TRE may slow neurodegeneration by 20%, offering hope for similar outcomes in HD.